

# Helle H Nielsen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5898283/publications.pdf>

Version: 2024-02-01

40  
papers

1,705  
citations

394390

19  
h-index

302107

39  
g-index

41  
all docs

41  
docs citations

41  
times ranked

2790  
citing authors

#	ARTICLE	IF	CITATIONS
1	Microglia Protect Neurons against Ischemia by Synthesis of Tumor Necrosis Factor. <i>Journal of Neuroscience</i> , 2009, 29, 1319-1330.	3.6	371
2	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1005-1015.	1.9	228
3	Toll-Like Receptor 2 Signaling in Response to Brain Injury: An Innate Bridge to Neuroinflammation. <i>Journal of Neuroscience</i> , 2006, 26, 12826-12837.	3.6	195
4	Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. <i>Neurology</i> , 2018, 91, e2265-e2275.	1.1	84
5	Migraine with aura and risk of silent brain infarcts and white matter hyperintensities: an MRI study. <i>Brain</i> , 2016, 139, 2015-2023.	7.6	74
6	Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, jnnp-2019-321321.	1.9	66
7	Characterization of the TNF and IL-1 systems in human brain and blood after ischemic stroke. <i>Acta Neuropathologica Communications</i> , 2020, 8, 81.	5.2	54
8	Migraine with visual aura associated with thicker visual cortex. <i>Brain</i> , 2018, 141, 776-785.	7.6	52
9	Neurofilaments: The C-Reactive Protein of Neurology. <i>Brain Sciences</i> , 2020, 10, 56.	2.3	47
10	A Urinary Metabolic Signature for Multiple Sclerosis and Neuromyelitis Optica. <i>Journal of Proteome Research</i> , 2016, 15, 659-666.	3.7	45
11	Acute Neurofilament Light Chain Plasma Levels Correlate With Stroke Severity and Clinical Outcome in Ischemic Stroke Patients. <i>Frontiers in Neurology</i> , 2020, 11, 448.	2.4	45
12	Fumarate decreases edema volume and improves functional outcome after experimental stroke. <i>Experimental Neurology</i> , 2017, 295, 144-154.	4.1	42
13	Differences in Origin of Reactive Microglia in Bone Marrow Chimeric Mouse and Rat After Transient Global Ischemia. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 481-494.	1.7	36
14	Efficacy of High-Intensity Aerobic Exercise on Brain MRI Measures in Multiple Sclerosis. <i>Neurology</i> , 2021, 96, e203-e213.	1.1	35
15	Enhanced Microglial Clearance of Myelin Debris in T Cell-Infiltrated Central Nervous System. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 845-856.	1.7	32
16	Stimulation of Adult Oligodendrogenesis by Myelin-Specific T Cells. <i>American Journal of Pathology</i> , 2011, 179, 2028-2041.	3.8	29
17	Axonal degeneration stimulates the formation of NG2+ cells and oligodendrocytes in the mouse. <i>Glia</i> , 2006, 54, 105-115.	4.9	28
18	Myelin-specific T cells induce interleukin-1 $\beta$ expression in lesion-reactive microglial-like cells in zones of axonal degeneration. <i>Glia</i> , 2016, 64, 407-424.	4.9	28

#	ARTICLE	IF	CITATIONS
19	Orthologous proteins of experimental de- and remyelination are differentially regulated in the CSF proteome of multiple sclerosis subtypes. <i>PLoS ONE</i> , 2018, 13, e0202530.	2.5	28
20	Dynamics of oligodendrocyte responses to anterograde axonal (Wallerian) and terminal degeneration in normal and TNF-transgenic mice. <i>Journal of Neuroscience Research</i> , 2004, 75, 203-217.	2.9	18
21	Axonal plasticity elicits long-term changes in oligodendroglia and myelinated fibers. <i>Glia</i> , 2010, 58, 29-42.	4.9	18
22	Efficacy of high-intensity aerobic exercise on cognitive performance in people with multiple sclerosis: A randomized controlled trial. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1585-1596.	3.0	18
23	The Urine Proteome Profile Is Different in Neuromyelitis Optica Compared to Multiple Sclerosis: A Clinical Proteome Study. <i>PLoS ONE</i> , 2015, 10, e0139659.	2.5	15
24	Investigating the potential disease-modifying and neuroprotective efficacy of exercise therapy early in the disease course of multiple sclerosis: The Early Multiple Sclerosis Exercise Study (EMSES). <i>Multiple Sclerosis Journal</i> , 2022, 28, 1620-1629.	3.0	15
25	Aerobic Capacity Is Not Associated with Most Cognitive Domains in Patients with Multiple Sclerosis—A Cross-Sectional Investigation. <i>Journal of Clinical Medicine</i> , 2018, 7, 272.	2.4	14
26	The Role of Non-Selective TNF Inhibitors in Demyelinating Events. <i>Brain Sciences</i> , 2021, 11, 38.	2.3	11
27	Omics-Based Approach Reveals Complement-Mediated Inflammation in Chronic Lymphocytic Inflammation With Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS). <i>Frontiers in Immunology</i> , 2018, 9, 741.	4.8	10
28	Migraine with aura in women is not associated with structural thalamic abnormalities. <i>NeuroImage: Clinical</i> , 2020, 28, 102361.	2.7	10
29	CSF proteome in multiple sclerosis subtypes related to brain lesion transcriptomes. <i>Scientific Reports</i> , 2021, 11, 4132.	3.3	10
30	Efficacy of high-intensity aerobic exercise on common multiple sclerosis symptoms. <i>Acta Neurologica Scandinavica</i> , 2022, 145, 229-238.	2.1	9
31	Leukocyte TNFR1 and TNFR2 Expression Contributes to the Peripheral Immune Response in Cases with Ischemic Stroke. <i>Cells</i> , 2021, 10, 861.	4.1	8
32	Autoantibodies Against the Complement Regulator Factor H in the Serum of Patients With Neuromyelitis Optica Spectrum Disorder. <i>Frontiers in Immunology</i> , 2021, 12, 660382.	4.8	7
33	Elevated Neurofilament Light Chain in Cerebrospinal Fluid and Plasma Reflect Inflammatory MRI Activity in Neurosarcoidosis. <i>Brain Sciences</i> , 2021, 11, 238.	2.3	6
34	Inflammatory profiles in plasma and cerebrospinal fluid of patients with neurosarcoidosis. <i>Journal of Neuroimmunology</i> , 2022, 367, 577849.	2.3	6
35	Population-based head-to-head comparison of the clinical characteristics and epidemiology of AQP4 antibody-positive NMOSD between two European countries. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 51, 102879.	2.0	3
36	Qualitative factors shaping MS patients'™ experiences of infusible disease-modifying drugs: a critical incident technique analysis. <i>BMJ Open</i> , 2020, 10, e037701.	1.9	2

#	ARTICLE	IF	CITATIONS
37	Hyperammonaemic Encephalopathy Caused by Adult-Onset Ornithine Transcarbamylase Deficiency. <i>Brain Sciences</i> , 2022, 12, 231.	2.3	2
38	Evaluation of functional outcome measures after fampridine treatment in patients with multiple sclerosis - An interventional follow-up study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 66, 104034.	2.0	2
39	Prevalence and Pattern of Craniofacial Pain and Headache in Danish Patients with Neuromyelitis Optica Spectrum Disorder. <i>European Neurological Review</i> , 2018, 13, 44.	0.5	1
40	Multiple sclerosis impairment scale and brain MRI in secondary progressive multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2022, 145, 332-347.	2.1	1